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ABSTRACT
Sleep disorders (SD) in patients with dementia are very common in clinical practice. The use 
of antidepressants with hypnotic actions, such as trazodone, plays an important role in these 
cases. The aim of this study is to present a profile of the use of trazodone in demented 
patients with SD, as well as a review of trazodone hydrochloride in SD. We evaluated 
178 elderly patients with Alzheimer’s disease and other dementias, clinically presenting 
SD and treated with hypnosedative medications. In the one-year period comprising the 
study, 68 (38.2%) of the 178 had sleep disorders. Most patients (114; 64%) had a diagnosis 
of Alzheimer’s disease. Approximately 85% of patients with SD used hypnosedative 
drugs. Trazodone was the most commonly used drug among patients (N = 35), with an 
effectiveness of 65.7%. Trazodone has been shown to be a good option for treatment of 
the elderly with dementia and associated SD.
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Trazodona para o tratamento de distúrbios do sono em demência: um estudo aberto, 
observacional e de revisão
RESUMO
Distúrbios do sono (DS) em pacientes com demência são muito comuns na prática clínica. 
O uso de antidepressivos com ação hipnótica, como a trazodona, tem um papel importante 
nesses casos. O objetivo desse estudo é apresentar um perfil do uso da trazodona em 
pacientes com demência e com DS, bem como revisar o cloridrato de trazodona no DS. 
Nós avaliamos 178 idosos com doença de Alzheimer (DA) e outras demências, clinicamente 
apresentando DS e que foram tratados com medicações hipnossedativas. No período de 
um ano de estudo, 68 (38,2%) tiveram DS. A maioria (114; 64%) tinham diagnóstico de DA. 
Aproximadamente 85% usaram fármacos hipnossedativos. A trazodona foi a mais utilizada 
(N=35), com evidência de melhora de 65,7%. A trazodona mostrou-se ser uma boa opção 
no tratamento de idosos com demência e DS associado.
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Sleep disorders are one of the major 
complications related to dementia and 
cause significant impacts on functional-
ity and quality of life in elderly patients1. 
These sleep disorders often contributes to 
institutionalization2.
The origin of sleep disorders in demen-
tia is usually multifactorial, resulting from 
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pathophysiological changes associated with the disease it-
self, sensory deprivations such as a reduction in audito-
ry and visual acuity, and changes in environmental stim-
uli such as light. Some studies have shown that damage 
to cholinergic neurons may contribute to changes in the 
sleep of patients with Alzheimer’s disease (AD)1.
Epidemiological surveys conducted in patients with 
AD have identified a prevalence of sleep disorders in up 
to 40% of patients with any stage of the disease3. 
A longitudinal study conducted with 76 elderly de-
mented patients over two years revealed that 24% of study 
participants used a hypnosedative drug chronically, in-
creasing from 3 to 17% in the first year, and remaining 
high at 13% in the second year4. In the study of Grace 
and colleagues, in which the use of hypnosedative drugs 
was recorded in less than 30% of patients with sleep dis-
orders, the authors argued that there was reluctance by 
doctors to use hypnotic drugs in demented patients with 
sleep disorders5. Appropriate treatment of sleep disorders 
may benefit both patients and their caregivers.
Antidepressants with hypnotic action, such as tra-
zodone, have played important roles in treating the el-
derly with sleep disorders, particularly in patients with 
dementia1. The therapeutic dose to induce sleep using 
these drugs is much smaller than that used for depres-
sion, showing effectiveness in inducing sleep and little 
mood alteration effects.
Trazodone has proved to be effective in the treatment 
of sleep disorders in depressed patients (not always old-
er)6-8, in secondary sleep disorders when compared to 
other substances9,10 and in healthy individuals11.
Assessments of the clinical response to trazodone hy-
drochloride for the treatment of sleep disorders in de-
mented patients may contribute to the pool of therapeu-
tic options for these patients.
The objective of this analysis was to establish a profile 
of the use of hypnosedative drugs in demented patients 
with sleep disorders, with an emphasis on trazodone hy-
drochloride and its effectiveness. This is an open-label, 
uncontrolled, observational study. General data and spe-
cific analysis of sleep disorders have been the aims of an-
other publication.
METHOD
This is a retrospective study that was previously ap-
proved by the Ethics Research Committee of the Univer-
sity of Brasilia. To be included, patients had to be diag-
nosed with dementia and followed for at least 12 months, 
during which time they were examined periodically ev-
ery two months. The visits of each patient during 2008 
and their records from visits in previous years since their 
first consultation were considered for selection and anal-
ysis. Among the 250 patients followed in the Geriatric 
Medical Centre of the University’s General Hospital in 
2008 (Cognitive Geriatric Unit), 128 were excluded: fol-
low-up of less than one year (n=39), mild cognitive im-
pairment (n=20), other possible causes of cognitive im-
pairment cognitive (depression, hypothyroidism, syphilis, 
use of medication and alcohol intake) (n=13). Sleep dis-
orders were present in 31.4% (56/178) of patients at the 
time of admission and in 38.2% (68/178) at end of follow-
up. Baseline characteristics for the patients are summa-
rized in Table 1. The Centre is accredited by the Ministry 
of Health as a reference center for patients with Alzheim-
er’s disease in the Brazilian Federal District.
Demographic and clinical data collected by interview 
and evaluation consisted of: gender, age, educational lev-
el, functionality, co-morbidities, aggressiveness, type of 
dementia and clinical data was gathered using the Objec-
tive Geriatric Assessment, a screening instrument devel-
oped for teaching and research in the Centre. Patients had 
complete physical examinations, laboratory tests [thy-
roid-stimulating hormone (TSH), vitamin B12, VDRL, 
biochemistry screen, and blood count] and imaging ex-
aminations [magnetic resonance imaging (MRI) and/or 
skull tomography].
The DSM-IV criteria12 were used for the diagnosis 
of dementia and those of NINCDS-ADRDA13 for AD 
(probable). Functionality was established using the As-
sessment of Instrumental Activities of Daily Life14. Mini 
Mental State Examination15 and Clinical Dementia Rat-
ing (CDR)16 were used in the cognitive assessment and in 
the characterization of the dementia stage, respectively.
 The NPI (Nighttime Behavior) scale includes eight 
items that are rated as to how often they occurred dur-
ing the past month17. Were considered to have a sleep 
disorder when all the following criteria: [1] Complaint 
of sleep disorder from patient or caregiver (NPI items - 
nighttime behavior); [2] Exhaustion of caregiver (score 
≥2; scale from 0 to 5, with 2 indicating mild distress).
Polysomnography and actigraphy were not per-
formed, and structured sleep diaries were not requested 
because of the low educational level of patients and care-
givers and the high proportion of patients with advanced 
degrees of dementia.
The presence of all of the items below (1 and 2) was 
the criterion for effectiveness in the treatment of sleep 
disorders: 1. Improvement of the sleep disorder com-
plaint. 2. Reduction in the exhaustion of the caregiver in 
the item of NPI that deals with night behavior disorders 
for 1 (minimum) or 0 (absent). 
The effectiveness percentile was calculated using the 
number of patients who showed evidence of improve-
ment in their sleep disorder by the total number of pa-
tients treated with this drug. Adverse events were collect-
ed by spontaneous (unsolicited) reporting.
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Table 1. Baseline characteristics of subjects. 
Characteristics N=178 (%) With SD (n=68) (%) Without SD (n=110) (%)
Educational level in years
   Illiterate 33 (18.5) 15 (22.1) 18 (16.4)
   Less than 4 years 80 (44.9) 33 (48.5) 47 (42.7)
   Between 4 and 8 years 33 (18.5) 10 (14.7) 23 (20.9)
   More than 8 years 32 (18.1) 10 (14.7) 22 (20)
Most frequent co-morbidities
   Systemic blood hypertension 105 (59) 38 (55.9) 67 (60.9)
   Dyslipidemia 38 (21.6) 13 (19.1) 25 (22.7)
   Diabetes mellitus 35 (19.7) 16 (23.5) 19 (17.3)
   Smoking 35 (19.7) 15 (22.1) 20 (18.2)
   Hypothyroidism 25 (14) 10 (14.7) 15 (13.6)
   Previous stroke 22 (12.4) 8 (11.8) 14 (12.7)
   Coronary artery disease 12 (6.7) 3 (4.4) 9 (8.2)
Functionality (IADL instrument)
   Dependent 137 (77) 52 (76.5) 85 (77.3)
   Independent 41 (23) 16 (23.5) 25 (22.7)
Types of dementias
   AD 114 (64) 43 (63.2) 71 (64.5)
   Mixed 24 (13.5) 9 (13.2) 15 (13.7)
   VD 13 (7.3) 7 (10.2) 6 (5.5)
   FTD 9 (5) 5 (7.4) 4 (3.6)
   LBD 7 (4) 2 (3) 5 (4.5)
   Others 11 (6.2) 2 (3) 9 (8.2)
CDR
   1 77 (43.2) 27 (39.7) 50 (45.5)
   2 85 (47.8) 35 (51.5) 50 (45.5)
   3 16 (9) 6 (8.8) 10 (9.1)
Report of aggressiveness
   Yes 109 (61.2) 46 (67.6) 63 (57.3)
   No 69 (38.8) 22 (32.4) 47 (42.7)
SD: sleep disorder; VD: vascular disease; FTD: frontotemporal dementia; LBD: Lewy body dementia; CDR: clinical dementia rating.
Table 2. Most commonly used drugs for the treatment of sleep disorders in patients 






Trazodone 35 23 (65.7) 50-100
Clonazepam 23 16 (69.5) 0.5-2
Mirtazapine 20 17 (85) 15-30
Mianserin 16 10 (62.5) 30
Others 13 9 (69.2) –
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 Statistical analysis was performed using SPSS ver-
sion 14.0 for Windows (SPSS, Chicago, USA). The data 
frequency was examined using the chi-squared test and 
t-tests were used to investigate baseline differences be-
tween genders. Statistical significance was set at p<0.05.
RESULTS 
Approximately 2/3 of patients (64.6%) were wom-
en and the mean age of the sample cohort was 79.1+7.4 
years. There was no difference between genders (p>0.05) 
with regards to average age. Most patients (114; 64%) had 
the diagnosis of AD.
The primary sleep disorder found among the elderly 
participants was difficulty in maintaining sleep at night 
(staying asleep). Difficulty in falling asleep, frequent 
arousals from sleep and early morning awakenings were 
observed. Although caregivers of our patients frequently 
complained about difficulties in sleep maintenance, the 
patients’ sleep disorders could not be classified. Table 2 
shows the most commonly used drugs for the treatment 
of sleep disorders in patients with dementia (some used 
more than one medication). 
The other drugs (N=13) were combined into a sin-
gle group known as “others”, represented by benzodiaz-
epines (triazolam, estazolam, and midazolam), antipsy-
chotics (olanzapine and thioridazine) and non-benzodi-
azepine inducers (zolpidem). 
The average time of use of antidepressants in months 
for the treatment of sleep disorders was 8.1 (±4) for tra-
zodone, 18.6 (±10.1) for mirtazapine and 19.3 (±6.8) for 
mianserin.
Trazodone was used at a dose of 50 mg/day (at bed-
time) in most patients (34) and 100 mg/day in one pa-
tient. No adverse effects were reported (spontaneously). 
In the cases where non-effectiveness of treatment was ex-
perienced (12), such non-effectiveness was observed from 
the first days of treatment, except for one case in which 
non-effectiveness began after 5 months of drug use.
DISCUSSION 
Trazodone is among the antidepressants used with 
good tolerability in this sample, showing effectiveness in 
2/3 of patients.
Antidepressants are a suitable option for the treat-
ment of sleep disorders in the elderly18. Tricyclic antide-
pressants such as amitriptyline, imipramine and cloimip-
ramine, have been used to induce sleep in patients with-
out dementia, especially when the sleep disorder is asso-
ciated with depression19. However, their anticholinergic 
action may lead to impaired cognition and risk of men-
tal confusion. 
Trazodone offers a dual action on serotonin recep-
tors by blocking serotonergic receptor 2A (5HT2A) and 
inhibiting serotonin reuptake. Phenylpiperazines are dif-
ferentiated from tricyclic antidepressants since they show 
greater selectivity for 5HT2A receptors. With regard to 
the blocking of serotonin reuptake, trazodone is less po-
tent than tricyclic antidepressants or selective serotonin 
reuptake inhibitors (SSRIs), and also blocks alpha 1 re-
ceptors. There is also a blockade of histaminergic recep-
tors, thus differing from nefazodone; this blocking of his-
taminergic receptors may be responsible for the extreme 
sedative effect of this drug. As a result of sleepiness in-
duced as a side-effect, even with off-label use, trazodo-
ne has been used in various circumstances in which the 
main goal is sleep induction20, but not in dements pa-
tients. Trazodone has also been used as an adjuvant to 
other antidepressants because it increases the tolerabili-


















Mean age (year) 30.1 43.5 61 44 23.9 42 24
Sleep onset  latency ↓ ↓ → → → → → →
% stage 2 ↑ → → ↑ ↑ ↓ → →
% stage 3, 4 ↑ ↑ → ↑ ↑ ↑ ↑ ↑
REM latency ↑ ↑ ↑ ↑ → → → ↑*
% REM → ↓ ↓ ↓ → → →
Total sleep time ↑ ↑ → → → → ↑ →
Nº of awakenings ↓ ↓ → ↓ ↓ ‡ ↓ ↓*
Dose used (mg/day) 400-600 150-400 300-400 150 50 50-100 100 200


















*not statistically significant; ↓decreased; ↑increased; → not change; ‡not evaluated; SD: sleep disorder.
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ty of these antidepressant by working to reduce their in-
duced adverse effects via the blocking of 5HT2A recep-
tors (stimulated by SSRI)21. 
The classic indication of trazodone is for depression, 
particularly when anxiety and insomnia are also present. 
The usual daily dose for improvement of the sleep disor-
der complaint varies between 150 and 200 mg/day. Ex-
treme doses of 50 and 600 mg/day may be used in specif-
ic cases. Lower doses, between 25 and 100 mg/day, have 
been prescribed as a hypnosedative for patients with in-
somnia and to correct the adverse effects of insomnia 
caused by SSRIs22. Due to its relative safety and its low 
inhibition of cholinergic receptors, trazodone has been 
used in the treatment of depression in elderly patients 
with cardiovascular disease. Reduced anticholinergic ef-
fect allows its use in elderly patients with cardiovascular 
impairments and delirium.
Most studies evaluating trazodone in the treatment 
of sleep disorders were conducted in patients with de-
pression. Saletu-Zyhlarz and collaborators, using poly-
somnography, evaluated 11 individuals with depression 
and sleep disorders and compared them to 11 healthy 
subjects. The authors observed an improvement in 
sleep parameters with the use of 100 mg/day of trazo-
done23. There was an increase in sleep total time, as we 
well as a reduction in nighttime and early awakenings. 
This study also reported improvements in the subjec-
tive quality of sleep, sleep efficiency, numerical memo-
ry and somatic complaints. This improvement in mem-
ory may be welcomed in cases of patients with demen-
tia. In our study, the patients did not use trazodone at 
doses higher than 100 mg/day, which may have contrib-
uted to a lower effectiveness when compared to mir-
tazapine. There appears to be some improvement in 
sleep parameters with increasing doses of trazodone6,7,10.
Nierenberg and colleagues reported good in subjec-
tive sleep parameters (PSQI - Pittsburgh Index) with the 
use of 50 mg/day of trazodone while evaluating patients 
with secondary insomnia with the use of antidepres-
sants24. Similar findings were observed by Kaynak using 
trazodone at a dose of 100 mg/day, with subjective and 
objective improvement of quality of sleep after one week 
of treatment10. 
Despite the improvement in sleep parameters re-
ported in most studies, polysomnographic findings vary 
among studies, probably due to differences in the dose 
used and age of the participants (Table 3). 
Trazodone has been shown to be effective in the el-
derly population mainly due to associated reduced anti-
cholinergic effects and undetectable electrocardiograph-
ic changes. Another important aspect of this drug is its 
good tolerability as a treatment for depression in elder-
ly patients. In the current study, 1/3 terminated treat-
ment with trazodone due to a lack of effectiveness but not 
due to adverse effects. The study of Lebert and colleagues 
showed no increase in adverse effects of trazodone in pa-
tients with dementia25.
The mechanism involved in the sedative effect of 
some antidepressants, among them trazodone, remains 
unclear. It is not known whether there is an improvement 
in sleep due to an improvement in depression or whether 
the improved sleep is due to the direct action of the med-
ication11. Kaynak and collaborators suggest that the ther-
apeutic effect of trazodone on sleep is independent of its 
antidepressant effect10. 
Trazodone and other antidepressants with strong an-
tagonism of 5-HT2 receptors have properties that in-
crease the slow-wave sleep in healthy volunteers and in 
depressed patients with insomnia26. 
The risk of priapism and trazodone-related cardiac 
arrhythmia is low and is only associated with high dos-
es. The alpha-adrenergic blockade caused by trazodone 
is thought to the mechanism responsible for priapism22. 
Limitations of this study include: absence of an 
instrument to ensure that all patients met diagnostic 
criteria for sleep disorders; the lack of a double-blind 
design; drugs eligibility was determined on the basis of 
physician’s clinical judgment, because this study sought 
to reflect the manner in which physicians treat SD in de-
ment elderly; information regarding the effectiveness of 
these drugs cannot be so clearly, since different drugs 
might be selected for different purposes. For example, 
a highly effective drug might look ineffective since doc-
tors might tend to use it only in the most refractory pa-
tients; absence of a placebo control group, it is not pos-
sible to draw definitive conclusions as one might with 
a randomized, blinded trial; under-reporting is a recog-
nized limitation of studies based upon spontaneous ad-
verse event reporting. 
Nonetheless, the results of this study, in an apparently 
representative cohort of demented elderly, provide use-
ful and clinically relevant information. This study was in-
tended to show the effectiveness of drugs (trazodone, spe-
cially) to SD in demented elderly under ‘real world’ con-
ditions and make a review. References are cited spanning 
at least three decades of research.
According to Erman, the lack of studies on the chron-
ic use of trazodone is a reflection of the lack of inter-
est by health authorities and pharmaceutical industries 
to develop controlled studies with placebo and double-
blind groups to assess the effectiveness and safety of the 
drug in these patients, since the drug has no more pat-
ent reserves27. The literature reveals the need for con-
trolled, prospective, double-blind and randomized stud-
ies to evaluate the benefits of trazodone in this particular 
segment of the population with dementia20,28,29.
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